Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O14813
UPID:
PHX2A_HUMAN
Alternative names:
ARIX1 homeodomain protein; Aristaless homeobox protein homolog; Paired-like homeobox 2A
Alternative UPACC:
O14813; A8K3N0; Q8IVZ2
Background:
Paired mesoderm homeobox protein 2A, also known as ARIX1 homeodomain protein, Aristaless homeobox protein homolog, and Paired-like homeobox 2A, plays a crucial role in the regulation of catecholamine biosynthetic genes. Acting as a transcription activator, it is pivotal in maintaining the noradrenergic phenotype, which is essential for the proper functioning of the nervous system.
Therapeutic significance:
The protein's involvement in congenital fibrosis of extraocular muscles type 2, a disorder characterized by restrictive ophthalmoplegia, highlights its clinical significance. Understanding the role of Paired mesoderm homeobox protein 2A could open doors to potential therapeutic strategies for this and related ocular motility disorders.